Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Stomach Neoplasms 3Breast Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms, Male 2Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pleural Effusion, Malignant 1Parathyroid Neoplasms 1

Interventions

Cytarabine 146Azacitidine 99venetoclax 95Cyclophosphamide 70fludarabine 69Decitabine 63fludarabine phosphate 55Specimen Handling 35Filgrastim 35Daunorubicin 34Mitoxantrone 30Idarubicin 29Etoposide 27Injections 25Granulocyte Colony-Stimulating Factor 25Biopsy 24Busulfan 22Tacrolimus 21Clofarabine 21Mycophenolic Acid 18Melphalan 18Methotrexate 17Bortezomib 17Whole-Body Irradiation 16Stem Cell Transplantation 16Peripheral Blood Stem Cell Transplantation 16Vorinostat 15Gemtuzumab 15Lenalidomide 14decitabine and cedazuridine drug combination 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myeloid, Acute × Interleukin-12 × Clear all
NCT02483312 2025-12-01

A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

University Health Network, Toronto

Phase 1 Active not recruiting
9 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡